Eli Lilly Medicare Obesity: $15B Market Boom Builds
Can Medicare coverage and faster FDA plant approvals turn Eli Lilly’s obesity franchise into an even bigger profit machine? Maik Kemper Editor in Chief From my perspective, both…
Eli Lilly LillyDirect +5.4% as Weight Watchers Expands Access
Can Eli Lilly LillyDirect turn obesity drugs into a full-service care platform that rivals cannot easily copy? Maik Kemper Editor in Chief LillyDirect is becoming the de facto…
Eli Lilly Zepbound Coverage +5.2% as CVS Restores Access
Can restored CVS access turn Eli Lilly Zepbound Coverage into the next big advantage in the obesity drug war? Maik Kemper Editor in Chief “Collaboration with pharmaceutical companies…
Eli Lilly Earnings Soar 156% as GLP‑1 Boom Lifts Outlook
Are Eli Lilly earnings finally proving that the GLP‑1 obesity boom can justify today’s sky‑high valuation? Maik Kemper Editor in Chief 2026 is off to a strong start,…
Eli Lilly Earnings Surge 56% as Stock Soars 8.3%
Can Eli Lilly’s explosive GLP-1 demand and raised outlook really justify one of the richest valuations in global pharma? Maik Kemper Editor in Chief “What we’re seeing now…
Novo Nordisk Wegovy Strategy Boom With HD Dose Push
Can Novo Nordisk’s aggressive Wegovy strategy really outflank Eli Lilly in the GLP-1 obesity war before new rivals scale up? Maik Kemper Editor in Chief The Wegovy HD…
Eli Lilly GLP-1 Strategy Boom and Revenue Shock
Can Eli Lilly’s GLP-1 boom keep powering the stock as regulation, lawsuits and ETF concentration risks close in? Maik Kemper Editor in Chief Conclusion The Eli Lilly GLP-1…